Submitted by Dr Tennie Videler on Wed, 16/07/2014 - 12:22
Cambridge Institute of Therapeutic Immunology and Infectious Disease receives £25 million of government funding
This project will bring together a broad range of key industry partners to achieve three inter-related ambitions. These are to:
- drive therapeutic breakthroughs in immune-related diseases
- explore new strategies for the control of globally important pathogens
- increase the likelihood of discovering important, high-value, new medicines in the UK by enhancing interactions between academia and the pharmaceutical industry.
in the project will focus on autoimmune and inflammatory disease – for example Type 1 diabetes and inflammatory bowel disease – and the looming threat posed by antimicrobial resistance.
HEFCE announced that it will invest £14.5 million in the new institute: http://www.hefce.ac.uk/whatwedo/rsrch/howfundr/ukrpif/cambsiid/
co-funded by Cambridge University with AstraZeneca/MedImmune, GlaxoSmithKline, UCB/Celltech, Kymab and the Wellcome Trust.
Cambridge News website: http://www.cambridge-news.co.uk/Business/Business-News/Cambridge-gets-major-new-funding-to-fight-disease-20140710105441.htm
More news will follow...
